Current perspectives on the pharmacologic treatment of boys and adolescents with congenital hypogonadotropic hypogonadism.
INTRODUCTION Congenital hypogonadotropic hypogonadism (CHH) in boys and adolescents requires age- and developmentally appropriate treatment to address androgen deficiency, testicular maturation, pubertal development, and ultimately fertility. The dynamic physiology of the hypothalamic-pituitary-testicular axis necessit...